Artelo Biosciences, Inc. Common Stock (ARTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ARTL trades at $1.43 with a market cap of $3.19M and a P/E ratio of 0.00. ARTL moved +3.68% today. Year to date, ARTL is -63.59%; over the trailing twelve months it is -91.84%. Its 52-week range spans $1.25 to $85.80. Rallies surfaces ARTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Artelo Biosciences Eyes Q4 2026 Phase 1 Dosing with $10.3M Cash: Artelo Biosciences reported a net loss of $3.0 million ($4.00/share) in Q1 2026 and held $10.3 million cash/investments, following a $0.8 million R&D expense. The company plans to initiate ART26.12 multiple ascending dose trial in Q4 2026 and is exploring ART27.13 expansion after interim Phase 2 CAReS data showing >6% weight gain.
| Metric | Value |
|---|---|
| Price | $1.43 |
| Market Cap | $3.19M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $85.80 |
| 52-Week Low | $1.25 |
| Volume | 9.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-9.83M |
| Gross Margin | 0.00% |
ARTL analyst coverage data. Average price target: $0.00.